BIOA — BioAge Labs Cashflow Statement
0.000.00%
Last trade - 00:00- $776.65m
- $498.20m
- $9.00m
Annual cashflow statement for BioAge Labs, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -39.7 | -63.9 | -71.1 | -80.6 |
| Depreciation | ||||
| Non-Cash Items | 2.62 | 19.6 | 8.24 | 10.6 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | 0.795 | 6.71 | 11.2 | -11.8 |
| Change in Accounts Receivable | ||||
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Cash from Operating Activities | -36.2 | -37.4 | -51.5 | -81.6 |
| Capital Expenditures | -0.103 | -0.166 | -0.366 | -0.719 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | 0 | -0.1 | — | -94.5 |
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Cash from Investing Activities | -0.103 | -0.266 | -0.366 | -95.2 |
| Financing Cash Flow Items | -0.045 | -0.063 | -5.05 | -0.4 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 2.5 | 34.9 | 381 | 11.5 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | -33.5 | -2.69 | 329 | -165 |